Tiny Drugmaker Soars on FDA Win to Treat Never-Ending Hunger (1)

Soleno Therapeutics jumped on Thursday after the drugmaker won US approval for its drug to treat insatiable hunger caused by a genetic disorder.

Shares of the Redwood City, California-based company climbed 38% — the biggest one-day gain since September 2023 — to their highest level in more than eight years.

The Food and Drug Administration approved Soleno’s pill to treat hyperphagia — a condition where individuals have a sense of being hungry all the time and never feeling satisfied — in adults and children four years or older. The condition is a feature of a genetic disorder called Prader-Willi syndrome ...